ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma

Xia, Lingfang; Zhou, Qi; Gao, Yunong; Hu, Wenjing; Lou, Ge; Sun, Hong; Zhu, Jianqing; Shu, Jin; Zhou, Xianfeng; Sun, Rong; Wu, Xiaohua*复旦大学; 哈尔滨医科大学; 重庆大学; 中国科学院研究生院
Nature Communications2022-12-8DOI: 10.1038/s41467-022-35133-4
7被引7阅读
引用收藏
分享

摘要

This phase 2 study assesses the efficacy and safety of camrelizumab (an anti-PD-1 antibody) plus famitinib (anti-angiogenic agent) in women with pretreated recurrent or metastatic cervical cancer (ClinicalTrials.gov NCT03827837). Patients with histologically or cytologically confirmed cervical squamous cell carcinoma experiencing relapse or progression during or after 1-2 lines of systemic therapy for recurrent or metastatic disease are enrolled. Eligible patients receive camrelizumab 200mg intravenously on day 1 of each 3-week cycle plus famitinib 20mg orally once daily. The primary endpoint is the objective response rate. Secondary endpoints are duration of response, disease control rate, time to response, progression-free survival, overall survival, and safety. The trial has met pre-specified endpoint. Thirty-three patients are enrolled; median follow-up lasts for 13.6 months (interquartile range: 10.0-23.6). Objective responses are observed in 13 (39.4%, 95% confidence interval [CI]: 22.9-57.9) patients; the 12-month duration of response rate is 74.1% (95% CI: 39.1-90.9). Median progression-free survival is 10.3 months (95% CI: 3.5-not reached) and the 12-month overall survival rate is 77.7% (95% CI: 58.9-88.7). All patients experience treatment-related adverse events; grade >= 3 events occur in 26 (78.8%) patients. Treatment-related serious adverse events and deaths are observed in 9 (27.3%) and 2 (6.1%) patients, respectively. Camrelizumab plus famitinib shows promising antitumor activity with a manageable and tolerable safety profile in patients with pretreated recurrent or metastatic cervical squamous cell carcinoma. This combination may represent a treatment option for this population. Patients with recurrent or metastatic cervical cancer have limited therapeutic options. Here the authors report efficacy and safety of camrelizumab (anti-PD-1 antibody) in combination with famitinib (anti-angiogenic agent) in pre-treated recurrent or metastatic squamous cervical cancer.

学科与关键词

关键词
OPEN-LABELSINGLE-ARMPATIENTS PTSCANCERSAFETYEFFICACYCHEMOTHERAPYEXPRESSIONSURVIVALBEVACIZUMAB
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Nature Communications
发表日期
2022-12-08
卷期
第 13 卷, 第 1 期
页码
7581
DOI
10.1038/s41467-022-35133-4
语言
ENGLISH
期刊等级
1区
成果收录
SCIE
资助标注
JiangsuHengrui PharmaceuticalsCo., Ltd.

作者

  • X

    Xia, Lingfang (第一作者)

    fudan univ

  • Z

    Zhou, Qi

    chongqing univ

查看全部 11 位作者收起作者
  • G

    Gao, Yunong

  • H

    Hu, Wenjing

  • L

    Lou, Ge

    harbin med univ

  • S

    Sun, Hong

    fudan univ

  • Z

    Zhu, Jianqing

    univ chinese acad sci · zhejiang canc hosp

  • S

    Shu, Jin

    chongqing univ

  • Z

    Zhou, Xianfeng

  • S

    Sun, Rong

  • W

    Wu, Xiaohua (通讯)

    fudan univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417